Jason Yongsheng Chan, Director of Research at SingHealth, shared a post on LinkedIn:
“In Singapore, we are fortunate to have access to life-saving but expensive CAR T-cell products under the Ministry of Health’s Cell, Tissue and Gene Therapy Product (CTGTP) framework. A typical treatment costs half a million dollars, and is heavily subsidised with a multi-layered financing system. Despite being late into the game – today, we can be confident that every eligible Singaporean patient will be able to access these forms of treatment.
We need to do more to ensure that we continue to make novel and effective medical therapies available in Singapore and in the larger Asian context.”
Quoting Edward Cliff’s post:
“Out in today’s issue of Blood Journals Portfolio, the final version of our study on global access to CAR T – thanks to Blood for making it a plenary paper!!
Check out the nicely rendered figures (great job Alex!) and the thoughtful accompanying commentary from Kristina Jenei LSE Department of Health Policy
Title: Improving access to chimeric antigen receptor T-cells for refractory or relapsing diffuse large B cell lymphoma therapy in Asia
Authors: Ya Hwee Tan, Dok Hyun Yoon, Andrew J. Davies, Christian Buske, Yang Liang Boo, Nagavalli Somasundaram, Francesca Lim, Shin Yeu Ong, Anand Jeyasekharan, Koji Izutsu, Won Seog Kim and Jason Yongsheng Chan.
Other articles featuring Jason Yongsheng Chan on OncoDaily.